Trial Outcomes & Findings for Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness (NCT NCT00637416)
NCT ID: NCT00637416
Last Updated: 2017-01-23
Results Overview
Change measured using voice assessment protocol-Grade, Roughness, Breathiness, Asthenia, Strain (GRBAS).
Recruitment status
TERMINATED
Study phase
PHASE4
Target enrollment
9 participants
Primary outcome timeframe
3 months
Results posted on
2017-01-23
Participant Flow
Participant milestones
| Measure |
Lansoprazole and Dietary Control
Lansoprazole and dietary control
Lansoprazole: Lansoprazole 30 mg taken by mouth daily for 3 months
|
Placebo and Dietary Control
Dietary control and placebo
Placebo: placebo taken by mouth daily for 3 months
|
|---|---|---|
|
Overall Study
STARTED
|
4
|
5
|
|
Overall Study
COMPLETED
|
3
|
3
|
|
Overall Study
NOT COMPLETED
|
1
|
2
|
Reasons for withdrawal
| Measure |
Lansoprazole and Dietary Control
Lansoprazole and dietary control
Lansoprazole: Lansoprazole 30 mg taken by mouth daily for 3 months
|
Placebo and Dietary Control
Dietary control and placebo
Placebo: placebo taken by mouth daily for 3 months
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
1
|
1
|
|
Overall Study
Unable to take study drug
|
0
|
1
|
Baseline Characteristics
Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness
Baseline characteristics by cohort
| Measure |
Lansoprazole and Dietary Control
n=4 Participants
Lansoprazole and dietary control
Lansoprazole: Lansoprazole 30 mg taken by mouth daily for 3 months
|
Placebo and Dietary Control
n=5 Participants
Dietary control and placebo
Placebo: placebo taken by mouth daily for 3 months
|
Total
n=9 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
4 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
9 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Gender
Female
|
2 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
|
Gender
Male
|
2 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
4 participants
n=5 Participants
|
5 participants
n=7 Participants
|
9 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 3 monthsPopulation: Study was stopped early, data were not collected, and zero participants were analyzed.
Change measured using voice assessment protocol-Grade, Roughness, Breathiness, Asthenia, Strain (GRBAS).
Outcome measures
Outcome data not reported
Adverse Events
Lansoprazole and Dietary Control
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Placebo and Dietary Control
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Director, ENT Clinical Research
University of Kansas Medical Center
Phone: (913) 588-7154
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place